Armistice Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Armistice Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155M	Buy	288,000 +23,417	+9%	+$12M	1.89%	3
2026 Q1	$139M	Sell	264,583 -1,122	-0.4%	-$536K	2.46%	5
2025 Q4	$155M	Buy	265,705 +145,723	+121%	+$74.4M	1.84%	4
2025 Q3	$55M	Sell	119,982 -4,018	-3%	-$1.5M	0.82%	18
2025 Q2	$37.5M	Sell	124,000 -11,883	-9%	-$3.54M	0.65%	25
2025 Q1	$45M	Buy	135,883 +35,883	+36%	+$11.8M	0.67%	30
2024 Q4	$30.9M	Buy	100,000 +50,085	+100%	+$14.1M	0.42%	43
2024 Q3	$10.6M	Sell	49,915 -100,085	-67%	-$25.6M	0.17%	92
2024 Q2	$42M	Sell	150,000 -18,000	-11%	-$4.28M	0.53%	32
2024 Q1	$44.9M	Buy	168,000 +118,000	+236%	+$27.8M	0.6%	25
2023 Q4	$11.6M	Sell	50,000 -58,000	-54%	-$10.1M	0.16%	76
2023 Q3	$15.8M	Sell	108,000 -28,000	-21%	-$5.27M	0.24%	67
2023 Q2	$31.4M	Sell	136,000 -140,000	-51%	-$37.9M	0.45%	44
2023 Q1	$66.9M	Buy	276,000 +68,000	+33%	+$18.5M	0.96%	25
2022 Q4	$60.4M	Sell	208,000 -1,028,000	-83%	-$101M	1.05%	25
2022 Q3	$80.3M	Buy	1,236,000 +136,000	+12%	+$9.45M	1.39%	17
2022 Q2	$78.7M	Buy	1,100,000 +122,000	+12%	+$8.97M	1.37%	15
2022 Q1	$96M	Sell	978,000 -146,000	-13%	-$12.3M	1.86%	11
2021 Q4	$95.2M	Buy	1,124,000 +88,000	+8%	+$7.23M	1.56%	11
2021 Q3	$82.7M	Buy	1,036,000 +444,000	+75%	+$38.4M	1.4%	14
2021 Q2	$57.7M	Buy	592,000 +242,000	+69%	+$28.6M	1.03%	23
2021 Q1	$40.9M	Buy	350,000 +34,000	+11%	+$3.96M	0.94%	37
2020 Q4	$35.1M	Buy	316,000 +38,000	+14%	+$4.64M	1.19%	24
2020 Q3	$33M	Buy	278,000 +30,000	+12%	+$3.26M	1.2%	28
2020 Q2	$28.1M	Buy	248,000 +32,000	+15%	+$3.15M	1.23%	30
2020 Q1	$14.4M	Buy	216,000 +56,000	+35%	+$4.67M	0.89%	41
2019 Q4	$14.6M	Buy	160,000 +52,000	+48%	+$5.04M	0.84%	37
2019 Q3	$9.31M	Sell	108,000 -300,000	-74%	-$28.1M	0.62%	43
2019 Q2	$42.8M	Sell	408,000 -17,000	-4%	-$1.82M	2.7%	7
2019 Q1	$53.2M	Buy	+425,000	New	+$52.8M	2.91%	6
2018 Q4	–	Sell	-80,000	Closed	-$17.1M	–	88
2018 Q3	$17.1M	Buy	+80,000	New	+$20.1M	1.03%	32
2018 Q2	–	Sell	-102,000	Closed	-$11.9M	–	82
2018 Q1	$11.9M	Buy	102,000 +42,000	+70%	+$5.18M	0.91%	38
2017 Q4	$5.51M	Sell	60,000 -152,000	-72%	-$8.68M	0.55%	47
2017 Q3	$9.54M	Sell	212,000 -70,000	-25%	-$1.31M	1.12%	35
2017 Q2	$4.58M	Buy	282,000 +154,000	+120%	+$2.41M	0.58%	45
2017 Q1	$1.97M	Buy	128,000 +4,000	+3%	+$62.9K	0.41%	42
2016 Q4	$1.85M	Sell	124,000 -8,000	-6%	-$129K	0.44%	45
2016 Q3	$1.67M	Buy	132,000 +114,857	+670%	+$1.11M	0.54%	41
2016 Q2	$156K	Buy	+17,143	New	+$206K	0.06%	46
2015 Q4	–	Sell	-57,143	Closed	-$3.48M	–	40
2015 Q3	$3.48M	Buy	+57,143	New	+$4.12M	1.19%	31
2015 Q2	–	Sell	-92,571	Closed	-$6.29M	–	30
2015 Q1	$6.29M	Buy	+92,571	New	+$7.94M	2.79%	17

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital's MDGL Position: Q2 2026 in Review

Armistice Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 8.9% in Q2 2026, buying an estimated $12M and bringing the position to 288,000 shares worth $155M. The position accounts for 1.89% of the portfolio, ranked #3.

Armistice Capital first reported a position in MDGL in Q1 2015 and has held it in 41 quarters since. The position peaked at $155M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Armistice Capital held 288,000 shares of Madrigal Pharmaceuticals worth $155M as of Q2 2026.
Armistice Capital bought 23,417 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $12M.
Madrigal Pharmaceuticals made up 1.89% of Armistice Capital's portfolio in Q2 2026, its #3 holding.
Armistice Capital first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 41 quarters since.
Armistice Capital's Madrigal Pharmaceuticals position peaked at $155M in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.